0001477932-22-002177.txt : 20220408 0001477932-22-002177.hdr.sgml : 20220408 20220408160217 ACCESSION NUMBER: 0001477932-22-002177 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220407 FILED AS OF DATE: 20220408 DATE AS OF CHANGE: 20220408 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TERRELL JASON BRADLEY MD CENTRAL INDEX KEY: 0001567531 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36833 FILM NUMBER: 22816943 MAIL ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY, STREET 2: SUITE 125, GALLERIA OAKS B CITY: AUSTIN STATE: TX ZIP: 78738 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY, STREET 2: SUITE 125, GALLERIA OAKS B CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 1 (646) 650-1351 MAIL ADDRESS: STREET 1: 13215 BEE CAVE PARKWAY, STREET 2: SUITE 125, GALLERIA OAKS B CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 4 1 form4.xml FORM 4 X0306 4 2022-04-07-05:00 false 0000093314 VOLITIONRX LTD VNRX 0001567531 TERRELL JASON BRADLEY MD 13215 BEE CAVE PARKWAY, SUITE 125, GALLERIA OAKS B AUSTIN TX 78738 false true false false Chief Medical Officer Common Stock 2022-04-07-05:00 4 A false 12300 0 A 37249 D Common Stock 2022-04-07-05:00 4 A false 955 0 A 955 I By Spouse Stock Option (Right to Buy) 3.40 2022-04-07-05:00 4 A false 22668 0 A 2031-08-03-05:00 Common Stock 22668 22668 D Stock Option (Right to Buy) 3.40 2022-04-07-05:00 4 A false 1760 0 A 2031-08-03-05:00 Common Stock 1760 1760 I By Spouse On August 3, 2021, the reporting person was awarded 35,145 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,300 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 6,150 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. On August 3, 2021, the spouse of the reporting person was awarded 2,730 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 955 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 477 units and 478 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the spouse of the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. On August 3, 2021, the reporting person was granted an option to purchase 64,766 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 22,668 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 11,334 shares on each of August 3, 2022 and August 3, 2023, respectively. On August 3, 2021, the spouse of the reporting person was granted an option to purchase 5,030 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,760 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 880 shares on each of August 3, 2022 and August 3, 2023, respectively. /s/ Jason Bradley Terrell MD 2022-04-08-05:00